Dosierungsschema von Vidofludimus zur Verwendung bei der Behandlung von Chronischen Entzündungs- Und/oder Autoimmunerkrankungen

Details

Veröffentlichungs-Nr.

EP4732905

Anmeldetag

22. November 2018

Veröffentlichung

29. April 2026

Rechtsraum

EP

IPC

A61K31/192, A61P29/00A61P29/00(4SC AG et al.)(GENZYME CORP et al.)

Abstract

The present invention refers to a 2-({3-fluoro-3'-methoxy-[1,1'-biphenyl]-4-yl}carbamoyl)cyclopent-1-ene-1-carboxylic acid) according to formula (I)and a novel dosage regimen as well as their uses in the treatment of chronic inflammatory and/or autoimmune diseases. The said compound of formula (I) inhibits dihydroorotate dehydrogenase (DHODH), and is known for the treatment and prevention of diseases, in particular their use in diseases where there is an advantage in inhibiting dihydroorotate dehydrogenase (DHODH).

Anmelder

Firma

Immunic AG

Land

🇩🇪 Deutschland

Fachgebiete